Oral News and Research

RSS

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

The chemical (S)-N'-nitrosonornicotine, or (S)-NNN, which is present in smokeless tobacco products, is a strong oral carcinogen, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Eisai, University of Kansas grant water-soluble pro-drug technology patent to OneWorld Health

OneWorld Health (OWH), a nonprofit that develops lifesaving medicines for neglected diseases, announced that it has signed a nonexclusive patent agreement with Eisai Co., Ltd., for a water-soluble pro-drug technology patent. OWH will use the pro-drug technology to advance development of iOWH032, its new drug to treat acute secretory diarrhea.

2 Apr 2012

Democrats offer optimistic take on court's health law decision

Appearing on the Sunday talk shows, Vice President Joseph Biden and Sen. Charles Schumer, D-N.Y., defended the health law and predicted it would be upheld by the high court.

2 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

First Edition: April 2, 2012

Today's headlines offer more analysis of what could become of the Supreme Courts consideration of the health law.

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

AngioDynamics presents NanoKnife System clinical study results at SSO 2012

AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced presentations on NanoKnife System clinical experience were given at the Society of Surgical Oncology (SSO) 2012 conference that took place March 21-24, 2012, in Orlando, Fla.

2 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Post-Supreme Court, political debate on health law heats up

Just a few days after the Supreme Court's marathon consideration of the health law, news coverage centered around political ramifications.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

High court's health law consideration has political repercussions

The pending ruling could be a stamp of "repudiation or endorsement" during the upcoming election season. But, if the court overturns the health law, will the GOP be prepared to turn the decision into political victory and could that outcome have a "silver lining" for the Obama administration?

31 Mar 2012

Course of state implementation efforts unchanged by high court's review

Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.

31 Mar 2012

Justices hold first vote today on health law's fate

If past practice holds, the Supreme Court will meet privately today to cast a preliminary vote. No one else will be present, and drafts of opinions are likely to be written and rewritten many times in the next few months before the actual decision is issued, likely sometime in June.

31 Mar 2012

Oral arguments inspire RNC ad

The Republican National Committee uses audio from Supreme Court oral arguments to craft a campaign ad criticizing President Barack Obama and the health law. Meanwhile, the Obama campaign has had a health law strategy of its own in place.

31 Mar 2012

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA).

31 Mar 2012

Perspectives: All this fuss about the word 'tax'; Civic lessons from the Supreme Court

It is now clear that the law will impose heavy burdens on state and family budgets and increasingly possible that its mandate that all Americans purchase health insurance or face penalties will be ruled unconstitutional. ... We and our Republican colleagues voted against the law two years ago and will continue to work toward a smarter, step-by-step solution that will make health care available to more Americans at a lower cost to the federal government, the states, and individuals seeking care.

31 Mar 2012

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.

31 Mar 2012

IMS supports new guidance on glucocorticoid use

The International Osteoporosis Foundation, along with the European Society for Calcified Tissue, launched new guidance on glucocorticoid use at the European Congress on Osteoporosis and Osteoarthritis (which took place in Bordeaux from March 21 - 24, 2012). Given the special relevance to postmenopausal women, the International Menopause Society (IMS) is supporting the publication of the guidance.

31 Mar 2012

Cancer patients with CDI may benefit from DIFICLIR drug

New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.

31 Mar 2012